Home > Insider Trading > Filing (0001062993-25-004985)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1521036	Lantheus Holdings Inc.	LNTH	In Vitro & In Vivo Diagnostic Substances (2835)	352318913

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1801395	Paul Blanchfield	C/O Lantheus Holdings, Inc. 201 Burlington Road, South Building Bedford MA 01730	President	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2025-03-05	2,084	$98.00	91,828	No	4	S	Direct
Common Stock	Acquisiton	2025-03-05	26,871	$0.00	118,699	No	4	A	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	A	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Acquisiton	2025-03-05	15,668	$0.00	15,668	$100.48

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
15,668		2035-03-05	No	4	A	Direct

Footnotes

The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2024.
Consists of 8,957 restricted stock units that vest in equal installments over a three-year period and 17,914 Total Shareholder Return performance-based restricted stock units ("PSUs") that cliff vest following a three-year performance period. The amount of PSUs included in this Report reflects the target award; however, the ultimate award size can range from 0% to 200% of the target based on the actual performance achieved at the end of the performance period.
The option vests in three equal annual installments beginning on March 5, 2026.